Xalaprost 0.005% (Ophthalmic Solution)

Indications

• Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension

Pharmacology

• Analogue of prostaglandin F2α
• Prostanoid selective FP receptor agonist
• Believed to reduce intraocular pressure by increasing the outflow of aqueous humor

Dosage & Administration

• Recommended dosage of 1 drop (1.5 mcg) in the affected eye(s) once daily in the evening
• Topical ophthalmic use only

Interaction

• In vitro studies show precipitation when mixed with eye drops containing thimerosal
• Administer with at least 5 minutes interval if using drugs containing thimerosal

Contraindications

• Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in the product

Side Effects

• Eyelash changes (increased length, thickness, pigmentation, number of lashes)
• Eyelid skin darkening
• Intraocular inflammation (iritis/uveitis)
• Iris pigmentation changes
• Macular edema, including cystoid macular edema
• Ocular adverse events and symptoms reported in 5-15% of patients (e.g., blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, punctate epithelial keratopathy)

Pregnancy & Lactation

• Pregnancy Category C
• No adequate and well controlled studies in pregnant women
• Use during pregnancy only if potential benefit justifies potential risk to the fetus

Precautions & Warnings

• May gradually increase pigmentation of the iris
• Eye color change due to increased melanin content in stromal melanocytes of the iris
• Increase in brown iris pigment not shown to progress further upon discontinuation of treatment
• Eyelid skin darkening, which may be reversible
• Possible increase in eyelash length, thickness, pigmentation, and number of lashes
• Misdirected growth of eyelashes
• Use with caution in patients with a history of intraocular inflammation (iritis/uveitis)
• Use with caution in patients without an intact posterior capsule or with known risk factors for macular edema

Use in Special Populations

• Pediatric Use: Safety and effectiveness not established in pediatric patients
• Geriatric Use: No overall differences in safety or effectiveness observed between elderly and younger patients

Therapeutic Class

• Drugs for miotics and glaucoma

Storage Conditions

• Before opening, keep the bottle in its box in a refrigerator (2°C-8°C) protected from light
• After opening, keep the bottle in its box in a cool place below 25°C
• Contents should be used within one month after the dropper is opened
• Keep out of reach of children

Related Brands

• Remaprost 0.005% (Ophthalmic Solution) - reman-drug-laboratories-ltd